2022年5月31日 · 在中国，Tibsovo于2022年2月获得国家药监局（NMPA）批准上市：该药是国内首个获批的IDH1抑制剂，用于治疗携带IDH1易感突变的复发或难治性急性髓系 ...

TIBSOVO is a prescription medicine used to treat adults with an isocitrate dehydrogenase-1 (IDH1) mutation with: acute myeloid leukemia (AML): with newly diagnosed AML treated in …

2018年7月20日 · Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called the isocitrate dehydrogenase-1 (IDH1) mutation, which can affect your bone …

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. [6] It is a small molecule inhibitor of …

艾伏尼布Ivosidenib （Tibsovo、拓舒沃®）是一种 口服强效IDH1抑制剂，2021年8月25日，美国FDA批准 施维雅 旗下产品Ivosidenib用于治疗经治携带IDH1突变的局部进展或转移性成人胆 …

TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by …

Tibsovo is a cancer medicine used to treat adults with: acute myeloid leukaemia (AML) that is newly diagnosed. For the treatment of AML, the medicine is used in combination with …

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid …

Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an …

TIBSOVO® treats patients with myelodysplastic syndromes, acute myeloid leukemia, & cholangiocarcinoma. See Full Indications & Prescribing Information.